Expression of HIF-1α and Glut-1 in human bladder cancer

  • Authors:
    • V. Palit
    • R. M. Phillips
    • R. Puri
    • T. Shah
    • M. C. Bibby
  • View Affiliations

  • Published online on: Saturday, October 1, 2005
  • Pages: 909-913
  • DOI: 10.3892/or.14.4.909

Abstract

HIF-1 is a heterodimer consisting of the HIF-1α and HIF-1β subunits, and HIF-1α is the unique oxygen regulated subunit that determines HIF-1 activity. HIF-1α upgrades many gene products which include the glucose transporter protein 1 (Glut-1). Immunohistochemical studies using a monoclonal antibody specific for HIF-1α indicate that the overexpression of HIF-1α occurs in the most common forms of human cancer, including bladder cancer. The expression of Glut-1 in human bladder cancer is associated with poor prognosis and a low survival rate. To our knowledge, this is the first study to compare the expression of both HIF-1α and Glut-1 with clinicopathological characteristics in superficial and invasive human bladder cancer (all invasive bladder cancer patients received radical radiotherapy). The Kaplan-Meier survival analysis curve shows a significant association of HIF-1α expression with recurrence and survival in superficial bladder cancer and shows a significant association of Glut-1 with survival in invasive bladder cancer [chi2 (4)=10.52; Pr >chi2 =0.0012].
Journal Cover

October 2005
Volume 14 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

2013 Impact Factor: 2.191
Ranked #33/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Palit, V., Phillips, R., Puri, R., Shah, T., & Bibby, M. (2005). Expression of HIF-1α and Glut-1 in human bladder cancer. Oncology Reports, 14(4), 909-913.
MLA
Palit, Phillips, Puri, Shah, and M. Bibby. "Expression of HIF-1α and Glut-1 in human bladder cancer." Oncology Reports Oncology Reports 14.4 (2005): 909-913.
Chicago
Palit, Phillips, Puri, Shah, and M. Bibby. "Expression of HIF-1α and Glut-1 in human bladder cancer." Oncology Reports Oncology Reports 14 no. 4 (2005): 909-913.